Sagent Pharmaceuticals ($SGNT) is widening its recall of antibiotics manufactured by one of its India-based contractors after a customer complained that small, dark particulate matter were found in the solution after it was reconstituted.
Sagent Pharmaceuticals will soon have a new Japanese owner, but for now any recalls are all on the U.S. injectable drug manufacturer. And it has another recall to deal with, this one of an antibiotic manufactured by one of its contractors in India.
Japan’s Nichi-Iko Pharmaceutical has a pipeline of biosimilars it hopes to sell in the U.S. and figures a beachhead there can only help. To enhance its chances, the drugmaker has struck a deal to acquire U.S. sterile injectables maker Sagent Pharmaceuticals for nearly three-quarters of a billion dollars.